ArticleEndocrine2014
Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients.
Article in Endocrine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- IGF Bioregulation System in Benign and Malignant Thyroid Nodular Disease: A Systematic Review.In vivo (Athens, Greece)Pooled it
- Article
- Clinical and Genetic Spectrum of Large AIP Deletions.Human mutation · 2026Article
- A rare case of Cushing's disease concurrent with papillary thyroid carcinoma.Caspian journal of internal medicine · 2021Article
- Insulin-Like Growth Factor Pathway and the Thyroid.Frontiers in endocrinology · 2021Review
- Added value of circulating miRNA expression profiling to sonographic TI-RADS classification in the diagnosis of thyroid nodules.Experimental and therapeutic medicine · 2020Article
- The tendency of reduced periodontal destruction in acromegalic patients showing similar inflammatory status with periodontitis patients.Endocrine · 2019Article
- Evaluation of the thyroid characteristics of patients with growth hormone-secreting adenomas.BMC endocrine disorders · 2019Article
- Article
- Growth hormone and insulin-like growth factor 1 affect the severity of Graves' disease.Endocrinology, diabetes & metabolism case reports · 2017Article
- Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.Journal of endocrinological investigation · 2015Article
- The clinical and cardiometabolic effects of d3-growth hormone receptor polymorphism in acromegaly.Pituitary · 2015Article
- Increased thyroid cancer risk in acromegaly.Pituitary · 2014Article
- Benign and malignant nodular thyroid disease in acromegaly. Is a routine thyroid ultrasound evaluation advisable?PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid diseases are frequently seen in patients with acromegaly. The aim of this study is to evaluate thyroid diseases and thyroid cancer in acromegalic patients followed in a single institution. The data of 92 acromegalic (43 male, 49 female) patients followed over 12 years were retrieved retrospectively from the hospital recordings. All available data for gender, age, body weight and height, duration of acromegaly, age at diagnosis of acromegaly, treatment methods for acromegaly and history of thyroid disease, serum GH, IGF-1, thyroid function tests, thyroid ultrasonography (US), thyroid scintigraphy and thyroid fine needle aspiration biopsy (FNAB) results were recorded for the patients. The mean age of the patients was 43.9 ± 10.8 years and the mean disease duration was 12 ± 6.9 years. Thyroid US was performed in 64 patients who had nodular or diffuse goiter on palpation during the post-treatment follow-up and nodules were found in 44 (47.8 %) patients. Final diagnosis in 64 patients with thyroid US results and thyroid function tests including 26 patients with FNAB were as follows: 31 (48.4 %) benign multinodular goiter (MNG), 6 (9.4 %) simple nodular goiter, 1 (1.6 %) toxic MNG, 1 (1.6 %) Hurthle cell adenoma, and 5 (7.8 %) differentiated thyroid cancer. In addition, 9 (14.1 %) patients had diffuse goiter. One of the patients with diffuse goiter had amiodarone induced thyrotoxicosis. Eleven (17.1 %) patients had normal thyroid US and no other thyroid disease. Patients with nodules had longer disease duration than patients without nodules (14.2 ± 6.6 vs. 9.4 ± 3.4 years, p = 0.043). Thyroid volume was positively correlated with post-treatment GH and post-treatment IGF-1 levels (r = 0.309, p = 0.041 and r = 0.423, p = 0.004), respectively. We found that 7.8 % of our acromegalic patients with thyroid US results were diagnosed with thyroid cancer. Therefore, acromegalic patients must be considered as a high risk group for the development of thyroid cancer and must be closely followed for thyroid nodules and tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.